Compare · DRUG vs LLY
DRUG vs LLY
Side-by-side comparison of Bright Minds Biosciences Inc. (DRUG) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DRUG and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $1.29T, about 2323.0x DRUG ($556.7M).
- LLY has been more active in the news (22 items in the past 4 weeks vs 2 for DRUG).
- LLY has more recent analyst coverage (25 ratings vs 9 for DRUG).
- Company
- Bright Minds Biosciences Inc.
- Eli Lilly and Company
- Price
- -
- -
- Market cap
- $556.7M
- $1.29T
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 2
- 22
- Recent ratings
- 9
- 25
Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest DRUG
- Bright Minds Biosciences Provides Update About Planned Study with BMB-101 in Developmental and Epileptic Encephalopathies
- Wolfe Research initiated coverage on Bright Minds Biosciences with a new price target
- SEC Form 6-K filed by Bright Minds Biosciences Inc.
- SEC Form 6-K filed by Bright Minds Biosciences Inc.
- Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference
- Bright Minds Biosciences to Present at Upcoming Conferences
- Amendment: SEC Form SCHEDULE 13G/A filed by Bright Minds Biosciences Inc.
- SEC Form S-8 filed by Bright Minds Biosciences Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Bright Minds Biosciences Inc.
- Vistagen Appoints Douglas J. Williamson to its Board of Directors
Latest LLY
- SEC Form 10-Q filed by Eli Lilly and Company
- SEC Form 8-K filed by Eli Lilly and Company
- Lilly reports third-quarter 2026 financial results, raises full-year guidance and highlights regulatory progress across the portfolio
- Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial
- Patrik Jonsson to retire after 36 years; Ilya Yuffa named president, Lilly Global Markets
- Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades
- Lilly declares fourth-quarter 2026 dividend
- Gabelli To Host 8th Annual Healthcare Symposium
- New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer
- Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026